E1E_1-degeneration and d′d′′d'd''-lemma

For a double complex $(A, d', d'')$, we show that if it satisfies the $d'd''$-lemma and the spectral sequence $\{E^{p, q}_r\}$ induced by $A$ does not degenerate at $E_0$, then it degenerates at $E_1$. We apply this result to prove the degeneration at $E_1$ of a Hodge-de Rham spectral sequence on compact bi-generalized Hermitian manifolds that satisfy a version of $d'd''$-lemma

Common wave behavior for mergers and acquisitions in OECD countries? a unique analysis using new Markov switching panel model approach

This paper investigates whether or not there is co-waved merger and acquisition (M&A) activity in 26 OECD countries. We apply the Markov Switching model to panel data (MSP hereafter), an approach which has not previously been attempted. Two distinct regimes are recognized in emerge from M&A data: the wave merger regime and normal merger regime. Our MSP captures the co-wave pattern of the sample countries and has a much better fit than either the univariate Markov Switching model or the conventional linear panel model.

Liquid biopsy genotyping in lung cancer: ready for clinical utility?

Liquid biopsy is a blood test that detects evidence of cancer cells or tumor DNA in the circulation. Despite complicated collection methods and the requirement for technique-dependent platforms, it has generated substantial interest due, in part, to its potential to detect driver oncogenes such as epidermal growth factor receptor (EGFR) mutants in lung cancer. This technology is advancing rapidly and is being incorporated into numerous EGFR tyrosine kinase inhibitor (EGFR-TKI) development programs. It appears ready for integration into clinical care. Recent studies have demonstrated that biological fluids such as saliva and urine can also be used for detecting EGFR mutant DNA through application other user-friendly techniques. This review focuses on the clinical application of liquid biopsies to lung cancer genotyping, including EGFR and other targets of genotype-directed therapy and compares multiple platforms used for liquid biopsy